Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 5,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.
Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centered value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualize relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalized and effective therapy adjustments. For better outcomes and true relief.
Since 2017, mySugr, one of the most popular diabetes management apps with more than 2 million registered users, is part of Roche Diabetes Care.
For more information please visit www.rochediabetes.com, www.accu-chek.com and www.mysugr.com.
The suite of solutions provided under the brands RocheDiabetes, Accu-Chek and mySugr offer people with diabetes and healthcare professionals' innovative and impactful solutions for convenient, efficient and effective diabetes management. It encompasses blood glucose meters, insulin delivery systems, lancing devices, digital health solutions as well as coaching and prevention programs – contributing to improved outcomes.
1. Source: Based on worldwide sales data reported by Roche, Lifescan, Ascencia, Abbott, Animas, Insulet Medtronic, Tandem and others.
2, 3, 4, 5, 6 Roche - Data on file.
